Changing the game: an examination of cutting-edge novel oncology screening tools

As of 2020, Charles River contributed to 83% of the FDA-approved cancer therapies on the market. We are equipped to introduce you to cutting-edge predictive screening tools to drive your therapy to market and start saving lives.

View this webinar to learn about trailblazing oncology screening tools such as a new 3D model platform and Implantable Microdevices (IMDs). This webinar will cover an array of topics including:

  • Common drug discovery challenges and how tools enhance your screening processes.
  • A new, rapid, and cost-effective 3D screening platform that recreates an environment of tumor, fibroblast and immune cells which allows for a better prediction of therapeutic performance in the clinic.
  • The benefits of utilizing IMDs which include systematically screening various individual and combination therapies in a small cohort of study animals, and facilitating the collection of robust data for numerous applications.
  • Determine how an extended panel of functional read-outs across different platforms can improve the candidate selection process and help develop translational biomarkers early in the drug development pipeline.
watch now
Watch the webinar on demand
Julia Schüler

Julia Schüler

Research Director, Charles River

Julia Schüler, PhD, studied veterinary medicine at the Freie Unversität Berlin (Germany) and at the Tierspital Zürich (Switzerland), where she received her DVM. She then joined the lab of Prof. Dr. Heiner Fiebig, founder of Oncotest GmbH, where she worked on orthotopic implantation of solid cancer PDX in immunocompromised mice.

After receiving her PhD from the University of Berlin, Dr. Schüler worked in the field of innate immunology at the Max-Planck Institute for Immunobiology, Freiburg, in the group of Dr. Marinus Lamers and Dr. Thomas Böhm, focusing on Toll-like receptor signaling. She later re-joined Oncotest, holding leadership positions in vivo contract research as well as R&D.

Julia is particularly interested in modeling tumor biology, the tumor microenvironment, hematological malignancies, translational biomarker research, immuno-oncology, and discovery platform development.

Kolin Hribar

Kolin Hribar

Ceo and Founder, Cypre

Kolin Hribar, PhD, founded Cypre in 2016 based on an unmet need for rapid and scalable 3D tumor models that predict therapeutic efficacy in patients. He has built Cypre with a passion for translational cancer research and a love for rapid innovation and iteration processes, enabled by high-performing, collaborative teams and a learner’s mindset. Kolin earned his PhD in Nanoengineering from UC San Diego and Bachelors and Masters degrees in Bioengineering from the University of Pennsylvania with Minors in Engineering Entrepreneurship and Music.

Oliver Jonas

Oliver Jonas

Scientific Founder, Kibur Medical

Oliver Jonas, Ph.D. is the scientific founder of Kibur Medical and Director of the Laboratory for Bio-Micro-Devices at Brigham & Women’s Hospital, Assistant Professor at Harvard Medical. He is also an Associate Member of the Broad Institute and of the Joint Center for Cancer Precision Medicine at the Dana-Farber Cancer Institute.

Dr. Jonas’ research focuses on new technologies for precision medicine, particularly through the development of microscale implantable drug delivery and sensing devices. Dr. Jonas is the inventor of the implantable microdevices (IMD) for high throughput in situ drug response measurements and has taken the technology from prototyping and in-vivo proof of concept into human applications. The Jonas laboratory at BWH/HMS also works on optical methods for detection of tissue responses and studies mechanisms of drug resistance in cancer.

Dr. Jonas was previously a postdoctoral fellow in the Langer Lab at the David H. Koch Institute for Integrative Cancer Research at MIT. Dr. Jonas holds a Ph.D. in Biophysics.

Arsalan Arif

Arsalan Arif

Founder & Publisher, Endpoints News

Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.